Salome Adam1,2, Daniela Doege2, Lena Koch-Gallenkamp3, Melissa S Y Thong2, Heike Bertram4, Andrea Eberle5, Bernd Holleczek6, Ron Pritzkuleit7, Mechthild Waldeyer-Sauerland8, Annika Waldmann8,9, Sylke Ruth Zeissig10, Lina Jansen3, Sabine Rohrmann2, Hermann Brenner3,11,12, Volker Arndt13. 1. Unit of Cancer Survivorship, Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany. 2. Division of Chronic Disease Epidemiology, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Hirschengraben 84, 8001, Zurich, Switzerland. 3. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany. 4. Cancer Registry of North Rhine-Westphalia, Gesundheitscampus 10, 44801, Bochum, Germany. 5. Bremen Cancer Registry, Leibniz Institute for Prevention Research and Epidemiology - BIPS, Achterstraße 30, 28359, Bremen, Germany. 6. Saarland Cancer Registry, Präsident Baltz Straße 5, 66119, Saarbrücken, Germany. 7. Schleswig-Holstein Cancer Registry, Ratzeburger Allee 160, 23562, Lübeck, Germany. 8. Hamburg Cancer Registry, Billstraße 80, 20539, Hamburg, Germany. 9. Institute of Social Medicine and Epidemiology, University Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany. 10. Cancer Registry of Rhineland-Palatinate, Große Bleiche 46, 55116, Mainz, Germany. 11. Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany. 12. German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany. 13. Unit of Cancer Survivorship, Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany. v.arndt@dkfz.de.
Abstract
BACKGROUND: Prostate cancer (PC) and its treatment may affect PC survivors differently with respect to age. However, little is known regarding age-specific health-related quality of life (HRQoL) in PC survivors 5 years or even ≥ 10 years post-diagnosis. METHODS: The sample included 1975 disease-free PC survivors (5-16 years post-diagnosis) and 661 cancer-free population controls, recruited from two German population-based studies (CAESAR+, LinDe). HRQoL in both populations was assessed using the EORTC QLQ-C30 questionnaire. Additionally, PC survivors completed the PC-specific EORTC QLQ-PR25 questionnaire. Differences in HRQoL between survivors and controls, as well as differences according to age and time since diagnosis were analyzed with multiple regression after adjustment for age, education, stage, and time since diagnosis, where appropriate. RESULTS: In general, PC survivors reported HRQoL and symptom-burden levels comparable to the general population, except for significantly poorer social functioning and higher burden for diarrhea and constipation. In age-specific analyses, PC survivors up to 69 years indicated poorer global health and social functioning than population controls. Stratification by time since diagnosis revealed little difference between the subgroups. On PC-specific symptoms, burden was highest for urinary bother and symptoms, and lowest for bowel symptoms. Younger age was associated with less urinary symptoms but higher urinary bother. CONCLUSION: Long-term disease-free PC survivors reported overall good HRQoL, but experienced persistent specific detriments. Our data suggest that these detriments do not improve substantially with increasing time since diagnosis. Targeted interventions are recommended to prevent PC-related and treatment-related symptoms becoming chronic and to enhance social functioning.
BACKGROUND:Prostate cancer (PC) and its treatment may affect PC survivors differently with respect to age. However, little is known regarding age-specific health-related quality of life (HRQoL) in PC survivors 5 years or even ≥ 10 years post-diagnosis. METHODS: The sample included 1975 disease-free PC survivors (5-16 years post-diagnosis) and 661 cancer-free population controls, recruited from two German population-based studies (CAESAR+, LinDe). HRQoL in both populations was assessed using the EORTC QLQ-C30 questionnaire. Additionally, PC survivors completed the PC-specific EORTC QLQ-PR25 questionnaire. Differences in HRQoL between survivors and controls, as well as differences according to age and time since diagnosis were analyzed with multiple regression after adjustment for age, education, stage, and time since diagnosis, where appropriate. RESULTS: In general, PC survivors reported HRQoL and symptom-burden levels comparable to the general population, except for significantly poorer social functioning and higher burden for diarrhea and constipation. In age-specific analyses, PC survivors up to 69 years indicated poorer global health and social functioning than population controls. Stratification by time since diagnosis revealed little difference between the subgroups. On PC-specific symptoms, burden was highest for urinary bother and symptoms, and lowest for bowel symptoms. Younger age was associated with less urinary symptoms but higher urinary bother. CONCLUSION: Long-term disease-free PC survivors reported overall good HRQoL, but experienced persistent specific detriments. Our data suggest that these detriments do not improve substantially with increasing time since diagnosis. Targeted interventions are recommended to prevent PC-related and treatment-related symptoms becoming chronic and to enhance social functioning.
Entities:
Keywords:
Health-related quality of life; Long-term survivor; Population-based; Prostate cancer
Authors: Carla Parry; Erin E Kent; Angela B Mariotto; Catherine M Alfano; Julia H Rowland Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-10 Impact factor: 4.254
Authors: Mechteld R M Visser; Frans J Oort; J Jan B van Lanschot; Jacobus van der Velden; Jaap J Kloek; Dirk J Gouma; Carolyn E Schwartz; Mirjam A G Sprangers Journal: Psychooncology Date: 2012-01-16 Impact factor: 3.894
Authors: George van Andel; Andrew Bottomley; Sophie D Fosså; Fabio Efficace; Corneel Coens; Stephane Guerif; Howard Kynaston; Paolo Gontero; George Thalmann; Atif Akdas; Sven D'Haese; Neil K Aaronson Journal: Eur J Cancer Date: 2008-09-05 Impact factor: 9.162
Authors: Katja Leuteritz; Diana Richter; Anja Mehnert-Theuerkauf; Jens-Uwe Stolzenburg; Andreas Hinz Journal: Qual Life Res Date: 2021-07-18 Impact factor: 4.147